Baseline Liver Fibrosis Severity Predicts Superior HBeAg Clearance and Fibrosis Reversal following Peg-IFNα plus Nucleos(t)ide Analog Therapy in HBeAg-positive Chronic Hepatitis B Patients [0.03%]
基线肝纤维化程度预测恩替卡韦联合干扰素治疗HBV感染者HBeAg血清学转换及肝纤维化的逆转优势
Yaqin Zhang,Fengxin Chen,Shuojie Wang et al.
Yaqin Zhang et al.
Background and aims: The impact of baseline liver fibrosis severity on the effectiveness of pegylated interferon (Peg-IFN) combined with nucleos(t)ide analogs (NAs) in the treatment of hepatitis B e antigen (HBeAg)-positi...
Referral-spectrum Effect in Hypercupriuric Referrals for Suspected Wilson Disease: Diagnostic Implications for Ceruloplasmin and 24-hour Urinary Copper Excretion [0.03%]
威尔逊病疑似患者的转诊频谱效应：对铜蓝蛋白和24小时尿铜排泄量诊断意义的影响
Yu Zhang,Yijun Bao,Yiting Wang et al.
Yu Zhang et al.
Background and aims: In contemporary practice, elevated 24-hour urinary copper excretion (24-h UCE) often triggers referral for suspected Wilson disease (WD). In this hypercupriuric referral setting, interpretation of 24-...
Danzhu Zhao,George Y Wu
Danzhu Zhao
Nitric oxide (NO) is a crucial regulator of hepatic and systemic vascular tone. Abnormal distribution of NO in various anatomical locations is a pathogenetic characteristic of portal hypertension. Under normal portal pressure conditions, li...
Evaluation of the Safety and Efficacy of SOF/VEL Treatment and Pre-treatment of TAF in Patients with Chronic Hepatitis B Virus/Hepatitis C Virus Coinfection: A Multicenter Study [0.03%]
评估索磷布韦维帕他韦联合或不联合艾美赛珠单抗治疗慢性乙型肝炎病毒/丙型肝炎病毒共感染患者的安全性和疗效：一项多中心研究
Yifan Han,Ning Lin,Dazhi Zhang et al.
Yifan Han et al.
Background and aims: Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection are among the leading causes of chronic liver diseases worldwide. Through the same transmission routes, HBV/HCV coinfection is w...
Mineralocorticoid Receptor Antagonists for Liver Fibrosis: Potential Mechanisms and Research Progress [0.03%]
矿物质皮质激素受体拮抗剂抗肝纤维化的潜在机制及研究进展
Huaijun Zheng,Ye Feng
Huaijun Zheng
Liver fibrosis is a central pathological process driving the progression of chronic liver disease, yet effective antifibrotic therapies remain limited. Increasing evidence has identified the mineralocorticoid receptor (MR), a ligand-activat...
Advances in Precise Assessment of Portal Pressure in Porto-sinusoidal Vascular Disease [0.03%]
门-窦型血管病肝静脉压力梯度异常的评估进展
Kun Zhu,Qingchun Fu,Muyun Liu
Kun Zhu
Porto-sinusoidal vascular disease (PSVD) is a non-cirrhotic vascular liver disorder characterized by portal and sinusoidal microvascular lesions and is frequently complicated by portal hypertension. Accurate assessment of portal pressure is...
Expanding the Horizon: A Roadmap for Artificial Intelligence Integration in Metabolic Dysfunction-associated Steatotic Liver Disease [0.03%]
展望未来：代谢功能障碍相关脂肪肝病的人工智能整合路线图
Abdulrahman Ismaiel,Stefan-Lucian Popa
Abdulrahman Ismaiel
Weiqi Duan,Qian Jian,Bo Sun et al.
Weiqi Duan et al.
Lipid metabolism reprogramming drives malignant proliferation and invasiveness in hepatocellular carcinoma (HCC). Beyond supplying energy and membrane components, lipids function as signaling molecules that modulate tumor cell epigenetics a...
FN1 Knockout Inhibits Tumorigenesis but Promotes Lung Metastasis in Hepatocellular Carcinoma [0.03%]
Fn1基因敲除抑制肝癌的原发肿瘤生长但促进肺转移
Meng Han,Xin Liu,Jian-Jun Gou et al.
Meng Han et al.
Targeting the 4EBP1/HSP90β/Nrf2 Axis Sensitizes β-catenin-mutant Hepatocellular Carcinoma to mTOR Inhibitors via Ferroptosis Induction [0.03%]
靶向4EBP1/HSP90β/Nrf2轴通过铁死亡诱导使CTNNB1突变的肝细胞癌对mTOR抑制剂敏感
Rong Li,Yi Zhou,Zimu Wang et al.
Rong Li et al.
Background and aims: The aberrant activation of the mTOR pathway and its crosstalk with other signaling cascades represent key drivers of hepatocellular carcinoma (HCC) progression. mTOR-mediated ferroptosis suppression h...